Blog | HemaCare

New HemaCare Publication Stipulates the Need for Healthy Donor Tissue

Jul 2, 2019 8:50:00 AM / by Nancy Andon, MSc posted in Apheresis, Cell Therapy

0 Comments

HemaCare has just announced the publication of their latest article in the popular stem cell industry periodical BioInformant. [1] The article focuses on the need for healthy donor starting material to keep up with growing demands in the cell and gene therapy industry.

Read More

HemaCare Rings in the New Year with New Headquarters and a Cutting-Edge Collection Center

Feb 5, 2019 10:08:00 AM / by Nancy Andon, MSc posted in GMP, Apheresis, Cell Therapy, cGMP, clinical grade compliance, clinical trial

0 Comments

HemaCare Corporation’s new global headquarters is officially open for business! The company started 2019 in a brand new 40,000 square foot space in a newly modernized 44-acre corporate campus located in the heart of the San Fernando Valley at Northridge. The design and construction of the cutting-edge facility provide a spacious workspace that promotes the well-being of its occupants, while significantly expanding the company’s on-site capabilities.

Read More

HemaCare Publication Illustrates Optimal Apheresis Collection Techniques

Oct 2, 2018 8:00:00 AM / by Nancy Andon, MSc posted in Apheresis, cell collection

0 Comments

Cell therapy research publication RegMedNet has just posted HemaCare’s latest article on how to use apheresis and cell collection techniques to optimize starting material quality. [1]

An Expansive Donor Network Helps Guarantee Consistent Quality

Apheresis donor material is intrinsically variable, yet a successful cell therapy product must have consistent efficacy across a wide range of patients. How do we reconcile these realities? As a large-scale apheresis supplier, HemaCare understands that quality raw materials are a matter of careful planning and expertise. Inter-donor variability can impact critical parameters including cell collection volume, cell subtype composition and cell proliferation potential. [2] Each of these parameters impact apheresis unit potency, and can impact resource use and manufacturing efficiency.

Read More

How to Optimize Material Quality for Cellular Therapeutics

Aug 15, 2018 10:10:00 AM / by Nancy Andon, MSc posted in Leukopak, Apheresis, cell quality, quality control

0 Comments

Last week, HemaCare published an article in Technology Networks discussing how optimal apheresis and collection methods give cell therapies a leading edge1 

Cell therapy is a unique field because the “products” are derived from living human cells and where each donor is different, variability is inevitable. Quality precursor material gives cell therapy products their best start. Variable or low-quality starting material introduces a need for complex separation strategies or repeated manufacturing runs, leading to higher costs and resource requirements.1 To ensure the process utilizes the right resources, scientists must adopt optimal apheresis instrumentation and collection methods as one of the most important steps. 

Read More

Everything You Need to Know About Apheresis

Mar 27, 2017 12:41:11 PM / by Stacy Matthews Branch, DVM, PhD posted in leukopaks, Apheresis, Innovation, leukemia

0 Comments

Many people have donated blood in their lifetime. This blood is not only used for transfusions, but to provide blood components to treat a number of diseases and to conduct research geared to develop new diagnostic and treatment strategies. To obtain specific blood components, the technique of apheresis is used. This procedure is the means to separate blood into its various components so that the desired one is removed. Then, the rest of the components are placed back into the donor’s circulation.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts